In last trading session, Genmab A/S (NASDAQ:GMAB) saw 0.63 million shares changing hands with its beta currently measuring 0.63. Company’s recent per share price level of $35.70 trading at $0.84 or 2.41% at ring of the bell on the day assigns it a market valuation of $23.81B. That closing price of GMAB’s stock is at a discount of -37.45% from its 52-week high price of $49.07 and is indicating a premium of 15.69% from its 52-week low price of $30.10. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.47 million shares which gives us an average trading volume of 424.51K if we extend that period to 3-months.
For Genmab A/S (GMAB), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 2.90. Splitting up the data highlights that, out of 28 analysts covering the stock, 4 rated the stock as a Sell while 1 recommended an Overweight rating for the stock. 10 suggested the stock as a Hold whereas 13 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of $0 in the current quarter.
Genmab A/S (NASDAQ:GMAB) trade information
Upright in the green during last session for gaining 2.41%, in the last five days GMAB remained trading in the red while hitting it’s week-highest on Tuesday, 01/11/22 when the stock touched $35.70 price level, adding 3.33% to its value on the day. Genmab A/S’s shares saw a change of -9.76% in year-to-date performance and have moved -1.63% in past 5-day. Genmab A/S (NASDAQ:GMAB) showed a performance of -2.19% in past 30-days. Number of shares sold short was 2.08 million shares which calculate 4.23 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of $45.52 to the stock, which implies a rise of 21.57% to its current value. Analysts have been projecting $29.43 as a low price target for the stock while placing it at a high target of $56.00. It follows that stock’s current price would drop -56.86% in reaching the projected high whereas dropping to the targeted low would mean a gain of 17.56% for stock’s current value.
Genmab A/S (GMAB) estimates and forecasts
Statistics highlight that Genmab A/S is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -17.40% of value to its shares in past 6 months, showing an annual growth rate of -41.07% while that of industry is 7.90. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. This year revenue growth is estimated to fall -19.30% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $319.59 million for the same. And 2 analysts are in estimates of company making revenue of $366.12 million in the next quarter that will end on Sep 2021. Company posted $877.24 million and $270.68 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -63.60% while estimating it to be 35.30% for the next quarter.
In 2022, company’s earnings growth rate is likely to be around 112.20% while estimates for its earnings growth in next 5 years are of 27.00%.
Genmab A/S is more likely to be releasing its next quarterly report in February and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
Genmab A/S (NASDAQ:GMAB)’s Major holders
Insiders are in possession of 0.00% of company’s total shares while institution are holding 7.19 percent of that, with stock having share float percentage of 7.19%. Investors also watch the number of corporate investors in a company very closely, which is 7.19% institutions for Genmab A/S that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at GMAB for having 6.85 million shares of worth $299.56 million. And as of Sep 29, 2021, it was holding 1.04% of the company’s outstanding shares.
The second largest institutional holder is Macquarie Group Limited, which was holding about 4.14 million shares on Sep 29, 2021. The number of shares represents firm’s hold over 0.63% of outstanding shares, having a total worth of $180.74 million.
On the other hand, iShares NASDAQ Biotechnology ETF and Vanguard Specialized-Health Care Fund are the top two Mutual Funds which own company’s shares. As of Oct 30, 2021, the former fund manager was holding 3.75 million shares of worth $167.23 million or 0.57% of the total outstanding shares. The later fund manager was in possession of 3.15 million shares on Oct 30, 2021, making its stake of worth around $140.63 million in the company or a holder of 0.48% of company’s stock.